Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
SV2C	rs2112865	AA	olanzapine	efficacy	no	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	Genotype AA is not associated with response to olanzapine in people with Schizophrenia as compared to genotypes AG + GG.	23886675	1183491211
SV2C	rs4580760	CC	olanzapine	efficacy	no	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	Genotype CC is not associated with response to olanzapine in people with Schizophrenia as compared to genotypes AA + AC.	23886675	1183491185
SV2C	rs7732173	AA	risperidone	efficacy	no	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score. In significant LD (r2 > 0.95) with rs10514062 and rs2358531.	Genotype AA is not associated with response to risperidone in people with Schizophrenia as compared to genotypes AG + GG.	23886675	1183491245
SV2C	rs11960832	TT	quetiapine	efficacy	no	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	Genotype TT is not associated with response to quetiapine in people with Schizophrenia as compared to genotypes CC + CT.	23886675	1183491237
SV2C	rs6874435	AA	olanzapine	efficacy	no	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	Genotype AA is not associated with response to olanzapine in people with Schizophrenia as compared to genotypes AG + GG.	23886675	1183491207
SV2C	rs2358531	GG	risperidone	efficacy	no	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score. In significant LD (r2 > 0.95) with rs10514062 and rs7732173.	Genotype GG is not associated with response to risperidone in people with Schizophrenia as compared to genotypes AA + AG.	23886675	1183491254
SV2C	rs10214163	TT	olanzapine	efficacy	no	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	Genotype TT is not associated with response to olanzapine in people with Schizophrenia as compared to genotypes CC + CT.	23886675	1183491195
SV2C	rs6882321	AA	risperidone	efficacy	no	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	Genotype AA is not associated with response to risperidone in people with Schizophrenia as compared to genotypes AC + CC.	23886675	1183491271
SV2C	rs10514062	TT	risperidone	efficacy	no	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score. In significant LD (r2 > 0.95) with rs7732173 and rs2358531.	Genotype TT is not associated with response to risperidone in people with Schizophrenia as compared to genotypes AA + AT.	23886675	1183491249
SV2C	rs10214163	TT	quetiapine	efficacy	no	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	Genotype TT is not associated with response to quetiapine in people with Schizophrenia as compared to genotypes CC + CT.	23886675	1183491220
SV2C	rs11960832	TT	olanzapine	efficacy	yes	Response was assessed by a change in the total Positive and Negative Syndrome Scale (PANSS) score. TT homozygotes had a smaller decrease or an increase in PANSS score compared to C allele carriers.	Genotype TT is associated with decreased response to olanzapine in people with Schizophrenia as compared to genotypes CC + CT.	23886675	1183491171
SV2C	rs2270927	CC	olanzapine	efficacy	no	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	Genotype CC is not associated with response to olanzapine in people with Schizophrenia as compared to genotypes CG + GG.	23886675	1183491203
SV2C	rs12522597	GG	ziprasidone	efficacy	no	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	Genotype GG is not associated with response to ziprasidone in people with Schizophrenia as compared to genotypes AA + AG.	23886675	1183491275
SV2C	rs31244	GG	quetiapine	efficacy	no	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	Genotype GG is not associated with response to quetiapine in people with Schizophrenia as compared to genotypes AA + AG.	23886675	1183491228
SV2C	rs1995380	GG	risperidone	efficacy	no	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	Genotype GG is not associated with response to risperidone in people with Schizophrenia as compared to genotypes CC + CG.	23886675	1183491258
SV2C	rs1995381	AA	olanzapine	efficacy	no	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	Genotype AA is not associated with response to olanzapine in people with Schizophrenia as compared to genotypes AG + GG.	23886675	1183491199
SV2C	rs2134227	GG	quetiapine	efficacy	no	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	Genotype GG is not associated with response to quetiapine in people with Schizophrenia as compared to genotypes CC + CG.	23886675	1183491224
SV2C	rs12655684	CC	ziprasidone	efficacy	no	Not significant after correction for multiple testing using the False Discovery Rate. Response was assessed by change in the total Positive and Negative Syndrome Scale (PANSS) score.	Genotype CC is not associated with response to ziprasidone in people with Schizophrenia as compared to genotypes CT + TT.	23886675	1183491287